AU2022270101A1 - Methods of treatment of autoimmune disorders using ilt7 binding proteins - Google Patents

Methods of treatment of autoimmune disorders using ilt7 binding proteins Download PDF

Info

Publication number
AU2022270101A1
AU2022270101A1 AU2022270101A AU2022270101A AU2022270101A1 AU 2022270101 A1 AU2022270101 A1 AU 2022270101A1 AU 2022270101 A AU2022270101 A AU 2022270101A AU 2022270101 A AU2022270101 A AU 2022270101A AU 2022270101 A1 AU2022270101 A1 AU 2022270101A1
Authority
AU
Australia
Prior art keywords
treatment
methods
binding proteins
autoimmune disorders
ilt7 binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022270101A
Other languages
English (en)
Inventor
Jorn DRAPPA
Edward Hammond
Gabor Illei
John Ratchford
William Rees
Li Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viela Bio Inc
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of AU2022270101A1 publication Critical patent/AU2022270101A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2022270101A 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins Pending AU2022270101A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163183886P 2021-05-04 2021-05-04
US63/183,886 2021-05-04
US202163197789P 2021-06-07 2021-06-07
US63/197,789 2021-06-07
US202163242768P 2021-09-10 2021-09-10
US63/242,768 2021-09-10
US202163249953P 2021-09-29 2021-09-29
US63/249,953 2021-09-29
US202263326424P 2022-04-01 2022-04-01
US63/326,424 2022-04-01
PCT/US2022/027620 WO2022235758A1 (en) 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins

Publications (1)

Publication Number Publication Date
AU2022270101A1 true AU2022270101A1 (en) 2023-10-05

Family

ID=82021082

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022270101A Pending AU2022270101A1 (en) 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins

Country Status (10)

Country Link
US (1) US20240287176A1 (https=)
EP (1) EP4333877A1 (https=)
JP (1) JP2024516698A (https=)
KR (1) KR20240004451A (https=)
AU (1) AU2022270101A1 (https=)
BR (1) BR112023023036A2 (https=)
CA (1) CA3217278A1 (https=)
IL (1) IL308132A (https=)
MX (1) MX2023013015A (https=)
WO (1) WO2022235758A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
AR130042A1 (es) * 2022-07-27 2024-10-30 Viela Bio Inc Formulaciones que comprenden una proteína de unión al transcripto 7 similar a inmunoglobulina (ilt7)
EP4593823A1 (en) * 2022-09-30 2025-08-06 Abbvie Inc. Methods of treating hidradenitis suppurativa
WO2024126431A1 (en) * 2022-12-12 2024-06-20 Horizon Therapeutics Ireland Dac Anti-ilt7 binding agents for the treatment and prevention of myositis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ616992A (en) * 2005-12-20 2015-07-31 Sbi Biotech Co Ltd Anti-ilt7 antibody
US20110311558A1 (en) * 2008-12-01 2011-12-22 The Board Of Regents Of The University Of Texas System Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
IL293572A (en) 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins

Also Published As

Publication number Publication date
BR112023023036A2 (pt) 2024-01-23
JP2024516698A (ja) 2024-04-16
WO2022235758A1 (en) 2022-11-10
MX2023013015A (es) 2023-11-15
EP4333877A1 (en) 2024-03-13
KR20240004451A (ko) 2024-01-11
US20240287176A1 (en) 2024-08-29
IL308132A (en) 2023-12-01
CA3217278A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
AU2022270101A1 (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
EP3856787A4 (en) SIRPalpha BINDING PROTEINS AND METHODS OF USE THEREOF
EP3856771A4 (en) Dll3 binding proteins and methods of use
EP3999110A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES
EP3917943A4 (en) PROTEINS PURIFICATION PROCEDURES
EP4051259A4 (en) METHOD OF TREATMENT USING A MMOC1 MODULATOR
EP3856169A4 (en) Methods of treating myeloproliferative disorders
EP3976082A4 (en) TREATMENT METHODS USING G-CSF PROTEIN COMPLEX
EP4260059A4 (en) PROTEIN ANALYSIS METHODS
EP4069724A4 (en) METHOD OF TREATMENT USING G-CSF PROTEIN COMPLEX
HK40101257A (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
EP3856189A4 (en) Methods of treating myeloproliferative disorders
EP3980066A4 (en) METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES
EP3755724A4 (en) COMPOSITION AND PROCESS
HK40073218A (en) Methods of treatment using ilt7 binding proteins
CA3286192A1 (en) Methods of use of multi-specific binding proteins
HK40130667A (en) Methods for treatment of autoimmune diseases
CA3288229A1 (en) Methods for treatment of autoimmune diseases
CA3308048A1 (en) Combination treatment of autoimmune disorders
AU2019901808A0 (en) CD39 binding proteins and methods of treating or preventing neurological diseases
HK40042100A (en) Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders
HK40065373A (en) Methods of protein purification
CA3296535A1 (en) Small molecules for the treatment of autoimmune disorders
CA3291424A1 (en) Cd8-specific binding proteins and methods of using the same
HK40103847A (en) Anti-ctla-4 binding proteins and methods of use thereof